CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-10-31): Hepatitis B genotype A predicts poor response to lamivudine

Clinical

Hepatitis B genotype A predicts poor response to lamivudine

Last Updated: 2006-10-31 14:55:13 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Among patients with Hepatitis B, response to lamivudine antiviral therapy is strongest among those with genotype B virus and poorest among those with genotype A, Japanese researchers report in the October issue of the Journal of Medical Virology.

Dr. Mariko Kobayashi and others at Toranomon Hospital in Tokyo studied response to lamivudine among 502 patients with hepatitis B virus infections. Fifteen patients had genotype A, 38 had genotype B and 449 had genotype C.

Median age of patients with genotype A was 37 years, compared with 47 years for genotype B and 44 years for patients with hepatitis B genotype C.

Hepatitis B e antigen (HbeAg) was present in 73% of patients with genotype A, in 21% with genotype B and in 56% with genotype C.

Hepatitis B DNA levels were higher in genotype A patients at 8.6 log genome equivalents (LGE)/mL, compared with 6.5 LGE/mL in patients with genotypes B and C.

Breakthrough hepatitis occurred in 47% of genotype A patients, compared with 21% of genotype B and 29% of genotype C patients. Genotype was a risk factor for hepatitis breakthrough only among patients who were HbeAg-positive.

YMDD mutants developed more often in genotype A patients compared with genotypes B and C. HBeAg seropositivity increased the risk of development of YMDD mutants.

"A therapeutic option for patients with genotype A who respond poorly to long-term lamivudine treatment may include adefovir dipivoxil that has a high efficacy unaccompanied by drug resistant mutants in patients with or without HbeAg," the investigators advise.

J Med Virol 2006;78:1276-1283.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.